Weak Panagglutination in a Symptomatic Patient Needing RBCs
A 58-year-old woman with myelodysplastic syndrome is admitted with fatigue and shortness of breath. CBC: Hb 6.8 g/dL, Hct 20%, platelets 45 × 10^9/L. She received 2 units of RBCs 4 weeks ago. Her type is A, Rh-positive, and the DAT is negative. Antibody screen by gel IAT: screen cells I and II reactive at 1+, screen cell III nonreactive. An 11-cell panel in gel IAT shows every cell reactive at 1+, while the autocontrol is negative. The patient is not actively bleeding but is symptomatic, and the clinician wants transfusion now. The blood bank has 4 units of A-positive RBCs on the shelf, none phenotyped. Reference laboratory turnaround is 24 hours.
1. How do you interpret the panel, and what testing would you perform next?
Read the worked answer
The pattern is a negative autocontrol with panreactivity in the panel, so a warm autoantibody is unlikely. The two main explanations are:
- An alloantibody against a high-prevalence antigen (for example, a Kidd, Kell, MNS, or Duffy-related high-incidence antigen).
- Multiple alloantibodies that together cover all panel cells.
The nonreactive screen cell III must be reconciled; check whether it is from a different lot or has weaker antigen expression, and repeat the screen with the panel cells.
Next steps:
- Phenotype the patient for Rh, Kell, Kidd, Duffy, and MNS antigens to see which specificities are excluded.
- Test ficin- or enzyme-treated panel cells; loss of reactivity suggests Duffy or MNS specificity, while enhancement suggests Rh or Kidd.
- Selected rare cells and a reference laboratory for high-incidence antigen identification.
- If the antibody remains unidentified, keep the patient on least-incompatible, phenotype-matched units and document the workup.
2. The patient is symptomatic and the workup will take 24 hours. How do you choose units now?
Read the worked answer
Do not withhold transfusion for an unstable, symptomatic patient with Hb 6.8 g/dL.
- Crossmatch all 4 shelf units by IAT and choose the unit with the weakest or no reactivity; "least incompatible" is acceptable when no compatible unit exists.
- Prefer units phenotypically matched for Rh and Kell (and for any specificity suggested by the panel) to reduce further alloimmunization.
- Because the antibody may target a high-prevalence antigen, notify the reference laboratory and the blood supplier early so rare-donor units can be located if the patient needs chronic transfusion.
- Transfuse slowly with physician awareness and bedside monitoring; document that the units are least incompatible.
- Recheck the antibody screen after transfusion, since additional alloantibodies can appear.
3. Six hours later the crossmatch is repeated and all 4 units are incompatible at 1+. What is the appropriate action?
Read the worked answer
This is expected when the antibody is directed at a high-prevalence antigen or when multiple alloantibodies are present; it does not mean the units are unsafe in an emergency.
- Confirm the autocontrol is still negative and that the reactivity is unchanged (rule out a new autoantibody or a technical issue).
- Contact the pathologist and the clinical team; transfusion of least-incompatible units is justified for symptomatic anemia when no compatible units can be found.
- Use phenotype-matched units where possible and give one unit at a time, reassessing symptoms and Hb.
- Watch for a delayed hemolytic transfusion reaction (falling Hb, rising bilirubin/LDH, positive DAT) by checking a post-transfusion sample at 24 hours and at 1–2 weeks.
- Continue the reference laboratory workup so future transfusions can be antigen-negative.